figuring out the actual risk of COX-2 inhibitors

Health Canada is getting closer to figuring out the actual risk of COX-2 inhibitors...and how to use them appropriately.

They will be adding new special warnings and dosage limits to the COX-2 inhibitors remaining on the market.

Vioxx might even come back in some countries. That's because now we know cardiovascular problems aren't unique to Vioxx...and it's the ONLY COX-2 so far that has proven GI benefits.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote